FrancophonIA/ELRC3.0 huggingface dataset:
English: Studies in patients with renal impairment revealed no clinically significant pharmacokinetic alterations or obvious side effects.
Croatian: Ispitivanja u bolesnika s oštećenjem funkcije bubrega nisu pokazala klinički značajne farmakokinetičke promjene ili očite nuspojave.
English: Aprotinin is indicated for prophylactic use to reduce blood loss and blood transfusion in adult patients who are at high risk of major blood loss undergoing isolated cardiopulmonary bypass graft surgery (i.e. coronary artery bypass graft surgery that is not combined with other cardiovascular surgery).
Croatian: Aprotinin je indiciran za profilaktičku primjenu kako bi se smanjio gubitak krvi i transfuzija krvi u odraslih bolesnika s visokim rizikom od velikog gubitka krvi u kojih će se provesti izolirana operacija ugradnje premosnice uz uporabu kardiopulmonalnog premoštenja (tj. operacija ugradnje premosnice koronarne arterije koja nije u kombinaciji s drugim kardiovaskularnim kirurškim zahvatima).
English: Laboratory monitoring of anticoagulation during cardiopulmonary bypass Aprotinin is not a heparin-sparing agent and it is important that adequate anticoagulation with heparin be maintained during aprotinin-therapy.
Croatian: Laboratorijsko praćenje antikoagulacije tijekom kardiopumonalnog premoštenja Aprotinin nije sredstvo koje štedi heparin i važno je da se tijekom terapije aprotininom održi odgovarajuća antikoagulacija heparinom.
English: Full-Dose Aprotinin
Croatian: Puna doza aprotinina
English: 6.6 Special precautions for disposal and other handling Parenteral drug products should be inspected visually for particulate matter and colour change prior to administration.
Croatian: 6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijekom Prije primjene, parenteralne lijekove treba vizualno pregledati da ne sadrže čestice i da nisu promijenili boju.
English: In rabbits, daily intravenous doses of 100,000 KIU/kg produced no evidence of maternal toxicity, embryotoxicity, fetotoxicity, or teratogenicity.
Croatian: U kunića, dnevne intravenske doze od 100 000 KIU/kg nisu proizvele nikakve dokaze toksičnosti za majku, embriotoksičnosti, fetotoksičnosti ili teratogenosti.
English: Adverse drug reactions (ADRs) based on all placebo-controlled clinical studies with aprotinin sorted by CIOMS III categories of frequency (aprotinin n=3817 and placebo n=2682; status: April 2005) are listed in the table below:
Croatian: Nuspojave na lijek temeljem svih placebom kontroliranih kliničkih ispitivanja aprotinina razvrstane prema kategorijama učestalosti CIOMS III (aprotinin n=3817 i placebo n=2682; status: travanj 2005) navedene su u tablici niže:
English: Rare: may affect up to 1 in 1,000 patients blood clot in blood vessels (arteries) severe allergic reaction (anaphylactic / anaphylactoid reaction)
Croatian: Rijetke: mogu se javiti u do 1 na 1000 bolesnika krvi ugrušak u krvnim žilama (arterije) teška alergijska reakcija (anafilaktička / anafilaktoidna reakcija)
English: Aprotinin should not be used when CABG surgery is combined with another cardiovascular surgery because the benefit risk balance of aprotinin in other cardiovascular procedures has not been established.
Croatian: Aprotinin se ne smije primjenjivati kad se operacija ugradnje koronarne premosnice kombinira s drugim kardiovaskularnim kirurškim zahvatom, zato što omjer koristi i rizika aprotinina u drugim kardiovaskularnim postupcima nije ustanovljen.
English: The incidence of serum creatinine elevations >2.0 mg/dL above baseline was similar (1.1 % vs 0.8 %) in both the full-dose aprotinin and placebo group, with an odds ratio of 1.16 (0.73 - 1.85) (see section 4.4).
Croatian: Incidencija povišenja kreatinina u serumu za >2,0 mg/dl iznad početne vrijednosti bila je slična (1,1 % naspram 0,8 %) u obje skupine, i one koja je primila punu dozu aprotinina i one koja je primila placebo, uz omjer šansi od 1,16 (0,73 - 1,85) (vidjeti dio 4.4).
English: Data from a global pool of placebo-controlled studies in patients undergoing coronary artery bypass graft (CABG) surgery showed that the incidence of serum creatinine elevations >0.5 mg/dL above pretreatment levels was statistically higher at 9.0 % (185/2047) in the full-dose aprotinin group compared with 6.6 % (129/1957) in the placebo group, with an odds ratio of 1.41 (1.12 - 1.79).
Croatian: Podaci iz globalne baze ispitivanja kontroliranih placebom u bolesnika kojima se ugrađuje aortokoronarna premosnica (CABG) pokazali su da je incidencija povišenog kreatinina u serumu za >0,5 mg/dl iznad razine prije liječenja bila statistički viša, tj. 9,0 % (185/2047) u skupini koja je primila punu dozu aprotinina u usporedbi sa 6,6 % (129/1957) u skupini koja je primila placebo, uz omjer šansi od 1,41 (1,12 - 1,79).
English: In case no aprotinin specific IgG antibody test is possible prior to treatment, administration of aprotinin to patients with a suspected previous exposure including in fibrin sealant products during the last 12 months is contraindicated.
Croatian: U slučaju da prije liječenja nije moguće provesti pretragu na IgG protutijelo specifično za aprotinin, primjena aprotinina je kontraindicirana u bolesnika sa sumnjom na prethodnu izloženost, uključujući fibrinsko ljepilo, u prethodnih 12 mjeseci.
English: A H1-antagonist and a H2-antagonist may be administered 15 minutes prior to the test dose of aprotinin.
Croatian: Mogu se primijeniti H1-antagonist i H2-antagonist 15 minuta prije probne doze aprotinina.
English: What you need to know before you are given <Aprotinin-containing medicinal product>
Croatian: Što morate znati prije nego dobijete <lijek koji sadrži aprotinin>
English: Mortality For the risk of mortality associated with the use of aprotinin see section 4.4.
Croatian: Rizik smrtnosti povezane s primjenom aprotinina vidjeti u dijelu 4.4.
English: • Determination of Heparin Levels
Croatian: • Određivanje razine heparina
English: If any of these occur during administration of <Aprotinin-containing medicinal product> your doctor/surgeon will stop treatment with the drug.
Croatian: Ako se ijedan od ovih simptoma pojavi tijekom primjene <lijeka koji sadrži aprotinin>, Vaš liječnik/kirurg prekinut će liječenje tim lijekom.
English: In aprotinin treated patients the neutralisation of heparin by protamine after discontinuation of cardiopulmonary bypass should either be based on a fixed ratio to the amount of heparin applied or be controlled by a protamine titration method.
Croatian: U bolesnika liječenih aprotininom, neutralizacija heparina protaminom nakon prekida kardiopulmonalnog premoštenja treba se temeljiti ili na fiksnom omjeru prema količini primijenjenog heparina ili biti kontrolirana pomoću metode titracije protaminom.
English: Patients with a positive aprotinin-specific IgG antibody test are at an increased risk of anaphylactic reaction when treated with aprotinin.
Croatian: Bolesnici s pozitivnim nalazom pretrage na IgG protutijelo specifično za aprotinin imaju povišeni rizik od anafilaktičke reakcije kad se liječe aprotininom.
English: Other medicines and <Aprotinin-containing medicinal product> Tell your doctor if you are taking, have recently taken or might take any other medicines.
Croatian: Obavijestite svog liječnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove.
English: The in-hospital mortality in a pool of randomized, clinical trials is summarized in the table below:
Croatian: Bolnička smrtnost u objedinjenim randomiziranim kliničkim ispitivanjima sažeta je u tablici niže:
English: • Fixed Heparin Dosing
Croatian: • Fiksne doze heparina
English: An appropriate aprotinin-specific IgG antibody test may be considered before administration of aprotinin (see section 4.3).
Croatian: Prije primjene aprotinina može se razmotriti provođenje odgovarajuće pretrage na IgG protutijelo specifično za aprotinin (vidjeti dio 4.3).
English: Any residual solution should not be kept for later use.
Croatian: Preostala otopina ne smije se čuvati za kasniju primjenu.
English: Very rare: may affect up to 1 in 10,000 patients swelling on or around the location of the injected skin (injection and infusion site reactions, infusion site (thrombo-) phlebitis) blood clot in the lungs (pulmonary embolism) severe blood clotting disorder that results in tissue damage and bleeding (disseminated intravascular coagulation) inability of the blood to clot or coagulate normally (coagulopathy) severe allergic shock (anaphylactic shock), which is potentially life threatening
Croatian: Vrlo rijetke: mogu se javiti u do 1 na 10 000 bolesnika oticanje kože na mjestu ili oko mjesta injiciranja (reakcije na mjestu injiciranja ili infuzije, (trombo-)flebitis na mjestu infuzije) krvni ugrušak u plućima (plućna embolija) teški poremećaj zgrušavanja krvi koji dovodi do oštećenja tkiva i krvarenja (diseminirana intravaskularna koagulacija) nesposobnost krvi da se normalno zgrušava ili koagulira (koagulopatija) teški alergijski šok (anafilaktički šok), koji može ugrožavati život
English: Uncommon: may affect up to 1 in 100 patients chest pain (myocardial ischaemia, coronary occlusion / thrombosis), heart attack (myocardial infarction) leakage of heart fluid into the surrounding body cavity (pericardial effusion) blood clot (thrombosis) kidney disease (acute renal failure, renal tubular necrosis) passing less urine than is normal
Croatian: Manje česte: mogu se javiti u do 1 na 100 bolesnika bol u prsištu (ishemija miokarda, koronarna okluzija/tromboza), srčani udar (infarkt miokarda) izljev srčane tekućine u okolnu tjelesnu šupljinu (perikardijalni izljev) krvni ugrušak (tromboza) bolest bubrega (akutno zatajenje bubrega, bubrežna tubularna nekroza) mokrenje manje količine mokraće nego što je normalno
English: • ADRs derived from post-marketing reports are printed in bold italic
Croatian: • Nuspojave na lijek izvedene iz prijava nakon stavljanja u promet otisnute su masnim kurzivom
English: An analysis of all pooled placebocontrolled studies in patients undergoing coronary artery bypass graft (CABG) has found elevations of serum creatinine values >0.5 mg/dL above baseline in patients with aprotinin therapy (see section 5.1).
Croatian: Analizom svih objedinjenih ispitivanja kontroliranih placebom u bolesnika kojima se ugradila premosnica koronarne arterije, u bolesnika na terapiji aprotininom pronađene su povišene vrijednosti serumskog kreatinina >0,5 mg/dl iznad početne razine (vidjeti dio 5.1).
English: Additional heparin should be administered in a fixed-dose regimen based on patient weight and duration of cardiopulmonary bypass.
Croatian: Dodatni heparin treba primijeniti u fiksnoj dozi na temelju tjelesne težine bolesnika i trajanja kardiopulmonalnog premoštenja.
English: If activated clotting time (ACT) is used to maintain adequate anticoagulation, a minimal celite-ACT of 750 seconds or kaolin-ACT of 480 seconds, independent of the effects of haemodilution and hypothermia, is recommended in the presence of aprotinin.
Croatian: Ako se koristi aktivirano vrijeme zgrušavanja (ACT) za održavanje odgovarajuće antikoagulacije, u prisutnosti aprotinina preporučuje se minimalno celitom aktivirano vrijeme zgrušavanja od 750 sekundi ili kaolinom aktivirano vrijeme zgrušavanja od 480 sekundi, neovisno o učincima hemodilucije i hipotermije.
English: Thus, aprotinin should only be used as authorized in isolated CABG surgery, after careful consideration of the potential risks and benefits.
Croatian: Stoga se aprotinin smije primjenjivati samo za to za što je odobren, tj. izoliranu ugradnju premosnice koronarne arterije, nakon pažljivog razmatranja mogućih rizika i koristi.
English: Contents of the pack and other information What <Aprotinin-containing medicinal product> contains [To be completed nationally]
Croatian: Sadržaj pakiranja i druge informacije Što <lijek koji sadrži aprotinin> sadrži [Ispunjava država članica]
English: Additional heparin should be administered on the basis of heparin levels measured by protamine titration.
Croatian: Dodatni heparin treba primijeniti na temelju razina heparina mjerenih titracijom protamina.
English: Results from recent observational studies indicate that renal dysfunction could be triggered by aprotinin, particularly in patients with pre-existing renal dysfunction.
Croatian: Rezultati najnovijih opažajnih ispitivanja pokazuju da aprotinin može biti okidač za poremećaj funkcije bubrega, osobito u bolesnika s već postojećim poremećajem funkcije bubrega.
English: In rat intravenous studies, daily doses of up to 80,000 KIU/kg produced no maternal toxicity, embryotoxicity, or fetotoxicity.
Croatian: U intravenskim ispitivanjima na štakorima, dnevne doze do 80 000 KIU/kg nisu izazvale toksičnost za majku, embriotoksičnost ili fetotoksičnost.
English: After intravenous injection, rapid distribution of aprotinin occurs into the total extracellular space, leading to an initial decrease in plasma aprotinin concentration with a half-life of 0.3 - 0.7 h. At later time points, (i.e. beyond 5 hours post-dose) there is a terminal elimination phase with a half-life of about 5 - 10 hours.
Croatian: Nakon intravenske injekcije dolazi do brze distribucije aprotinina u cjelokupni izvanstanični prostor, što dovodi do početnog sniženja koncentracije aprotinina u plazmi uz poluvijek od 0,3 - 0,7 sati.
English: If you have kidney problems <Aprotinin-containing medicinal product> should only be used if your doctor/surgeon feels it will be of benefit.
Croatian: Ako imate tegobe s bubrezima, <lijek koji sadrži aprotinin> smije se primjeniti samo ako Vaš liječnik/kirurg smatra da će to biti od koristi.
English: You must not be given <Aprotinin-containing medicinal product>
Croatian: Ne smijete dobiti <lijek koji sadrži aprotinin>
English: What <Aprotinin-containing medicinal product> is and what it is used for What you need to know before you are given <Aprotinin-containing medicinal product> How to use <Aprotinin-containing medicinal product> Possible side effects
Croatian: Što je <lijek koji sadrži aprotinin> i za što se koristi Što morate znati prije nego dobijete <lijek koji sadrži aprotinin>
English: If any of these apply to you, your doctor will decide whether <Aprotinin-containing medicinal product> is suitable for you or not.
Croatian: Ako se nešto od navedenog odnosi na Vas, liječnik će odlučiti je li <lijek koji sadrži aprotinin> pogodan za Vas.
English: Marketing Authorisation Holder and Manufacturer [See Annex I - To be completed nationally] {Name and address} <{tel}> <{fax}> <{e-mail}>
Croatian: Nositelj odobrenja za stavljanje gotovog lijeka u promet i proizvođač [Vidjeti Dodatak I - Ispunjava država članica] {Ime i adresa} <{tel}> <{fax}> <{e-mail}>
English: What <Aprotinin-containing medicinal product> looks like and contents of the pack [To be completed nationally]
Croatian: Kako <lijek koji sadrži aprotinin> izgleda i sadržaj pakiranja [Ispunjava država članica]
English: If you are pregnant or breast-feeding <Aprotinin-containing medicinal product> should only be used if your doctor/surgeon finds it will be of benefit.
Croatian: Ako ste trudni ili dojite, <lijek koji sadrži aprotinin> smije se primijeniti samo ako Vaš liječnik/kirurg smatra da će to biti od koristi.
English: Common: ≥ 1/100 to < 1/10
Croatian: Često: ≥1/100 do <1/10
English: While protocols vary, a minimal celite ACT of 750 seconds or kaolin ACT of 480 seconds, independent of the effects of haemodilution and hypothermia, is recommended in the presence of aprotinin.
Croatian: Dok se protokoli razlikuju, u prisutnosti aprotinina preporučuje se minimalno celitom aktivirano vrijeme zgrušavanja od 750 sekundi ili kaolinom aktivirano vrijeme zgrušavanja od 480 sekundi, neovisno o učincima hemodilucije i hipotermije.
English: PHARMACEUTICAL FORM [To be completed nationally]
Croatian: OBLIK [Ispunjava država članica]
English: 4.5 Interaction with other medicinal products and other forms of interaction Aprotinin has a dose-dependent inhibitory effect on the action of thrombolytic agents, e.g. streptokinase, urokinase, alteplase (r-tPA).
Croatian: Aprotinin ima inhibicijski učinak ovisan o dozi na djelovanje trombolitičkih sredstava, npr. streptokinaze, urokinaze, alteplaze (r-tPA).
English: A further 1 - 2 million KIU should be added to the pump prime of the heart-lung machine. To avoid physical incompatibility of aprotinin and heparin when adding to the pump prime solution, each agent must be added during recirculation of the pump prime to assure adequate dilution prior to admixture with the other component.
Croatian: Da bi se izbjegla fizička inkompatibilnost aprotinina i heparina, kad se dodaju u otopinu za pokretanje stroja, svaki od njih se mora dodati tijekom recirkulacije otopine za pokretanje stroja kako bi se osiguralo odgovarajuće razrjeđenje prije nego što se jedna komponenta pomiješa s drugom.
English: Disseminated intravascular coagulation Coagulopathy
Croatian: Poremećaji krvi i limfnog sustava diseminirana intravaskularna koagulacija, koagulopatija
English: Renal dysfunction could be triggered by aprotinin, particularly in patients with pre-existing renal dysfunction.
Croatian: Aprotinin može biti okidač za poremećaj funkcije bubrega, osobito u bolesnika s već postojećim poremećajem funkcije bubrega.
English: Rare: ≥ 1/10,000 to < 1/1,000
Croatian: Rijetko: ≥1/10 000 do <1/1000
English: NAME OF THE MEDICINAL PRODUCT <Aprotinin-containing medicinal product> [See Annex I - To be completed nationally]
Croatian: NAZIV LIJEKA <lijek koji sadrži aprotinin > [Vidjeti Dodatak I - ispunjava država članica]
English: Hepatic impairment No data are available on dosage recommendations for patients with hepatic dysfunction.
Croatian: Nema dostupnih podataka o preporučenim dozama za bolesnike s oštećenjem funkcije jetre.
English: Coronary occlusion/ thrombosis Myocardial infarction Pericardial effusion
Croatian: Srčani poremećaji ishemija miokarda, koronarna okluzija/ tromboza, infarkt miokarda, perikardijalni izljev
English: You should specifically tell your doctor if you take: - medicines used to dissolve blood clots, such as streptokinase, urokinase, alteplase (r-tPA) - aminoglycosides (antibiotics, medicines used to treat infections)
Croatian: Osobito trebate napomenuti svom liječniku ako uzimate: - lijekove koji se primjenjuju za otapanje krvnih ugrušaka, kao što su streptokinaza, urokinaza,
English: Elevations in the partial thromboplastin time (PTT) and celite Activated Clotting Time (Celite ACT) are expected in aprotinin-treated patients during surgery, and in the hours after surgery.
Croatian: U bolesnika liječenih aprotininom tijekom operacije, kao i u satima nakon operacije, očekuje se produljenje parcijalnog tromboplastinskog vremena (PTT) i celitom aktiviranog vremena zgrušavanja (Celite ACT).
English: How to use <Aprotinin-containing medicinal product>
Croatian: Kako primjenjivati <lijek koji sadrži aprotinin>
English: A heparin dose response, assessed by protamine titration, should be performed prior to administration of aprotinin to determine the heparin loading dose.
Croatian: Prije primjene aprotinina treba provjeriti odgovor na dozu heparina, procijenjen pomoću titracije protaminom, kako bi se odredila udarna doza heparina.
English: Uncommon: ≥ 1/1,000 to < 1/100
Croatian: Manje često: ≥1/1000 do <1/100
English: if no aprotinin specific IgG antibody test is possible prior to treatment and you have received or you suspect that you have received <Aprotinin-containing medicinal product> in the last 12 months.
Croatian: ako je dostupan pozitivan test na IgG protutijelo specifično za aprotinin, koji pokazuje povećan rizik od alergijske reakcije na <lijek koji sadrži aprotinin>. ako prije liječenja nije moguće provesti test na IgG protutijelo specifično za aprotinin, a Vi ste primili ili sumnjate da ste primili <lijek koji sadrži aprotinin> u prethodnih 12 mjeseci.
English: Standard emergency treatment for allergic/anaphylactic reactions should be readily available during treatment with aprotinin.
Croatian: Tijekom liječenja aprotininom potrebno je imati spremno standardno hitno liječenje alergijskih/anafilaktičkih reakcija.
English: <Aprotinin-containing medicinal product>
Croatian: <Lijek koji sadrži aprotinin>
English: Injection and infusion site reactions Infusion site (thrombo-) phlebitis
Croatian: Opći poremećaji i reakcije na mjestu primjene reakcije na mjestu injiciranja ili infuzije, (trombo-)flebitis na mjestu infuzije
English: In the pooled analysis of all placebo-controlled clinical studies, the incidence of investigator-reported myocardial infarction (MI) in aprotinin treated patients was 5.8 % compared to 4.8 % in placebo treated patients, with difference of 0.98 % between the groups (aprotinin n=3817 and placebo n=2682; status: April 2005).
Croatian: 4,8 % u bolesnika liječenih placebom, uz razliku od 0,98 % između skupina (aprotinin n=3817 i placebo n=2682; status: travanj 2005).
English: Standard emergency treatment for severe allergic reactions should be readily available during treatment with <Aprotinin-containing medicinal product>.
Croatian: Tijekom liječenja <lijekom koji sadrži aprotinin> potrebno je imati na raspolaganju spremno standardno hitno liječenje za teške alergijske reakcije.
English: Oliguria, acute renal failure, renal tubular necrosis
Croatian: Poremećaji bubrega i mokraćnog sustava oligurija, akutno zatajenje bubrega, bubrežna tubularna nekroza
English: An increase in renal failure and mortality compared to age-matched historical controls has been reported for aprotinin-treated patients undergoing cardiopulmonary bypass with deep hypothermic circulatory arrest during operation of the thoracic aorta.
Croatian: U bolesnika liječenih aprotininom kod kardiopulmonalnog premoštenja uz dugotrajni hipotermijski cirkulatorni arest tijekom operacije torakalne aorte zabilježeno je povećanje zatajenja bubrega i smrtnosti u usporedbi s povijesnim kontrolama odgovarajuće dobi.
English: Cardiovascular system: hypotension Skin and appendages: pruritus, rash, urticaria Digestive system:
Croatian: astma (bronhospazam) Kardiovaskularni sustav: hipotenzija Koža i kožni adneksi:
English: Allergic reaction Anaphylactic / anaphylactoid reaction
Croatian: Poremećaji imunološkog sustava alergijska reakcija, anafilaktička / anafilaktoidna reakcija anafilaktički šok (potencijalno životno opasan)
English: Protamine titration, a method that is not affected by aprotinin, can be used to measure heparin levels.
Croatian: Za mjerenje razine heparina može se koristiti titracija protamina, metoda na koju aprotinin ne utječe.
English: 6.2 Incompatibilities [To be completed nationally]
Croatian: 6.2 Inkompatibilnosti
English: SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
Croatian: Sadržaj pakiranja i druge informacije
English: 6.3 Shelf life [To be completed nationally]
Croatian: 6.3 Rok valjanosti [Ispunjava država članica]
English: Strength Pharmaceutical Form Route of Administration
Croatian: Farmaceutski oblik Put primjene Unutarnje pakovanje
English: • Drink alcohol, see Insulatard with alcohol in section 2.
Croatian: • pijete alkohol, pogledajte Insulatard s alkoholom u dijelu 2.
English: Insulatard will start to lower your blood sugar about 1½ hours after you inject it, and the effect will last for approximately 24 hours.
Croatian: Insulatard će početi snižavati razinu šećera u krvi oko 1½ sat nakon što ga injicirate, a učinak će trajati približno 24 sata.
English: Insulatard which has been frozen must not be used.
Croatian: Insulatard koji je bio zamrznut ne smije se primijeniti.
English: What Insulatard is and what it is used for
Croatian: Što je Insulatard i za što se koristi
English: Insulatard dosing is individual and determined in accordance with the needs of the patient.
Croatian: Doziranje lijeka Insulatard individualno je i određuje se u skladu s potrebama bolesnika.
English: Insulatard with alcohol
Croatian: Insulatard s alkoholom
English: Other medicines and Insulatard
Croatian: Drugi lijekovi i Insulatard
English: Contents of the pack and other information What Insulatard contains
Croatian: Sadržaj pakiranja i druge informacije Što Insulatard sadrži
English: This should be kept in mind if treatment with the combination of pioglitazone and Insulatard is considered.
Croatian: Ovo treba imati na umu ako se razmatra liječenje kombinacijom pioglitazona i lijeka Insulatard.